智通财经APP获悉，据港交所1月1日披露，上海万怡医学科技股份有限公司(简称：万怡医学)向港交所主板递交上市申请，光大证券国际为其独家保荐人。 公司简介 于2023年度、2024年度以及2025年截至9月30日止九个月，公司实现收益分别约为2.39亿元(人民币，下同)、2.71亿元、1.91亿元。 年度╱期间溢利 于2023年度、2024年度以及2025年截至9月30日止九个月，公司录得年度╱期间溢利分别约为2986.8万元、2971.9万元、3688.4万元。 | | 截至12月31日止年度 | | 截至9月30日止九個月 | | | --- | --- | --- | --- | --- | | | 2023 年 | 2024年 | 2024年 | 2025年 | | | 人民幣千元 人民幣千元 | | 人民幣千元 | 人民幣千元 | | | | | (未經審核) | (未經審核) | | 收益 ... | 238,767 | 271.064 | 177,829 | 190.657 | | 销售成本 :: : | (148,284) | (174,307) | (114,039) | (110,074) ...

12月19日，科创板公司深圳市道通科技股份有限公司（简称"道通科技"，证券代码：688208）公告称向 香港联交所递交H股发行上市申请，并于同日递交了招股书。 招股书显示，道通科技是领先的数智车辆诊断及智慧充电解决方案提供商。公司坚持前沿技术创新，并 积极探索具身智能集群领域，致力于提供AI驱动的软硬件深度融合的解决方案，以满足客户不断变化 的需求，助力构建以人为本的智能未来。 公司产品主要为数智车辆诊断、智慧充电及其他，按照2025年上半年的数据，前述三项业务收入占比分 别为76.4%、22.5%、1.1%。 道通科技称，从数智车辆诊断业务来看，按2022年、2023年及2024年收入计算，公司是全球第一的数智 车辆诊断解决方案提供商，市场份额从2022年的9.1%增长到2024年的11.1%。 财务数据显示，2022年至2024年及2025年上半年（以下简称"报告期"），道通科技收入分别为22.66亿 元、32.51亿元、39.32亿元、23.45亿元；年/期内利润分别为0.82亿元、1.40亿元、5.60亿元、4.55亿 元。 事实上，道通科技业务重心在海外，来自欧美地区的营收长年占比在70%左右。按照 ...

Financial Data and Key Metrics Changes - Total revenue for Q2 was RMB 379 million, a decrease of 7% year over year, primarily due to a decline in medical service providers subscribing to information services [15] - Aesthetic treatment service revenues reached RMB 144 million, an increase of 426% year over year, exceeding guidance [15] - Net loss attributable to the company was RMB 36 million, compared to a net income of RMB 18.9 million in the same period last year [19] - Non-GAAP net loss was RMB 30.5 million, compared to a non-GAAP net income of RMB 22.2 million in the same period of 2024 [19] - Basic and diluted losses per ADS were RMB 0.35, compared to earnings of RMB 0.18 in the same period last year [19] Business Line Data and Key Metrics Changes - Revenue from aesthetics center business reached RMB 144 million, marking it as the largest revenue segment for the first time [4] - Aesthetic treatment services revenue increased by 46% quarter over quarter and 426% year over year [5] - Total number of verified treatment visits surpassed 67,400 in Q2, up 24% quarter over quarter and 381% year over year [7] - The overall repeat purchase rate for the aesthetic center business exceeded 60% [7] Market Data and Key Metrics Changes - The light medical aesthetic market in China is expected to reach around RMB 26 billion by 2030, with a penetration rate forecasted to reach 30% [30] - The company aims to achieve a market share of roughly 25% in the light medical aesthetic sector [30] Company Strategy and Development Direction - The company plans to open around 10 aesthetic centers in the third quarter, targeting a total of 50 centers by year-end [11] - The focus is on expanding in both first-tier and core second-tier cities, enhancing accessibility to medical aesthetic services [11] - The company is committed to optimizing user experience and operational efficiency to strengthen its competitive edge [13] Management Comments on Operating Environment and Future Outlook - Management remains optimistic about the growth potential of China's medical aesthetic market, citing a current penetration rate below 5% [30] - The company expects aesthetic treatment service revenues to be between RMB 150 million and RMB 170 million in the upcoming quarter, representing a significant increase from the same period in 2024 [20] - The company emphasizes the importance of sustainable low-cost customer acquisition and a diversified upstream supply chain [31] Other Important Information - The company has maintained a robust cash position with cash and cash equivalents totaling RMB 98.6 million as of June 30, 2025 [20] - The gross profit margin for aesthetic treatment services expanded by around five percentage points sequentially [8] Q&A Session Summary Question: Expansion plan for C and I payment and franchise model - The company aims to grow the number of centers to 50 by the end of this year, with plans for more than 10 openings in the second half [24] - Long-term, the target is to achieve 1,000 centers within eight to ten years, with franchising being a future focus [25][26] Question: Growth potential of the Chinese medical aesthetics market - Management is optimistic about the market, with substantial growth potential indicated by a low current penetration rate [30] - The company plans to focus on three core capabilities to maintain its competitive edge [31] Question: Outlook for customer acquisition cost and marketing expenses - The average customer acquisition cost remains low, with over 70% of new customers coming from referrals [34] - The company plans to enhance brand visibility through localized marketing initiatives [34] Question: Recruitment of doctors and reliance on center managers - There is a solid base for recruiting doctors, with many moving from public hospitals to the medical aesthetic sector [40] - The company operates on a model that reduces reliance on center managers, improving operational efficiency [42] Question: Differentiation in product strategy - The product strategy focuses on anti-aging treatments, ensuring consistency and overall cost-effectiveness across the portfolio [46] - The company aims to optimize its product portfolio based on market demand and competitive trends [48] Question: Updates on the POP business - The POP business remains a key pillar of profitability, with plans to promote synergies between POP and aesthetic center businesses [50]